Trabectedin, a new option emerging from the sea for patients with relapsed ovarian cancer
2010-10-23 - English

After viewing this presentation the participant will be able to:
- Describe the properties and mechanism of action of trabectedin

An increasing role for trabectedin in gynaecological cancers: efficacy in uterine sarcomas
2010-10-23 - English

After viewing this presentation the participant will be able to:
- Review the incidence and epidemiology of uterine sarcoma
- Discuss data regarding the use of trabectedin for the treatment of uterine sarcoma

Safety profile of trabectedin: considerations for good management
2010-10-23 - English

After viewing this presentation the participant will be able to:
- Review the toxicity profile of Yondelis-PLD combination described in the OVA-301 study
- Discuss data from the OVA-301 study regarding patient quality of life

Benefits of enhancing the platinum-free interval in the treatment of relapsed ovarian cancer: more than just a hypothesis?
2010-10-23 - English

After viewing this presentation the participant will be able to:
- Describe data from studies regarding non-platinum therapy
- Discuss data regarding treatment options for partially platinum-sensitive relapse
- Be aware of the benefits of platinum-free interval extension with a non-platinum agent

Efficacy of trabectedin in platinum-sensitive relapsed ovarian cancer: new data from the randomized study OVA 301
2010-10-23 - English

After viewing this presentation the participant will be able to:
- Review main results of the OVA-301 study
- Be aware of ongoing studies comparing platinum-free interval with a non-platinum agent

Conclusions
2010-10-23 - English